顺铂放射增强效果在鼻咽癌病人中的临床观察  

Prospective Randomized Trial of Radiotherapy Plus Cisplatin(DDP)for Nasopharyngeal Carcionoma

作　　者：郭小毛[1] 刘瑛[1] 何少琴[1] 

机构地区：[1]上海医科大学附属肿瘤医院

出　　处：《齐鲁肿瘤杂志》1996年第3期203-204,共2页

摘　　要：顺铂作为一种广谱抗肿瘤药物，它具有放射增强作用，尤其对于头颈部肿瘤中疗效明显提高，并且不增加急性反应，病人能耐受。本文采用前瞻性随机研究，对已确诊为鼻咽癌并有颈部淋巴结转移的７９例病人随机分为单纯放射组（Ⅰ组）和放射联合顺铂组（Ⅱ组）。放射治疗均采用同中心摆位，总量７０Ｇｙ／３５～３７次／７～８周。顺铂自放射开始后使用，１次／周，２０ｍｇ／ｍ２／次，共７～８次。分别以颈部转移性淋巴结缩小５０％和颈部皮肤干性脱皮来评价肿瘤组织放射效应及早期放射反应，结果获得治疗增益比提高１４％。急性反应主要是恶心、呕吐、口腔炎及干、湿性脱皮，但所有病人均能耐受而完成治疗。Ninety eight patients with nasopharyngeal carcinoma were randomized into radiotherapy alone group (Arml.48 cases)and radiotherapy plus DDPgroup(Arm2.50 cases).Radiotherapy was demonstrated isocentrally for all patients,and the total dose of 70Gy/35 37 fractions /7 8 weeks.Cisplatin was given with 20mg/m 2 once week for 7 8 weeks.The results showed that patients in Arm2 had higher CR rate than in Arml.Followed up for three years (median 40 months),the three year survival rate was 76% in Arml and 83% in Arm2.The acute and late reaction were more severe in Arm2 than that in Arml,but all were tolerable.

关 键 词：鼻咽癌 放射治疗 顺铂 

分 类 号：R739.63[医药卫生—肿瘤]